Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical Advantage Over Enzalutamide Alone in First-Line Treatment of mCRPC

Press/Media

Period	6 Apr 2023

Media coverage

Title	Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical Advantage Over Enzalutamide Alone in First-Line Treatment of mCRPC
Media name/outlet	ESMO
Country/Territory	Switzerland
Date	6/04/23
URL	https://www.esmo.org/oncology-news/combination-of-enzalutamide-plus-abiraterone-acetate-and-prednisone-offers-no-clinical-advantage-over-enzalutamide-alone-in-first-line-treatment-of-mcrpc
Persons	Michael Morris